Nanomerics Reports Last Volunteer Visit in the OC134 Sunlight Trial; The Sunlight Trial Met Its Primary Endpoints
Nanomerics Ltd. announced the successful completion of its OC134 Phase I trial - the SUNLIGHT trial. With the clinical phase competed the trial for OC134 and the MET platform has met its primary endpoints.
LONDON, UK / ACCESS Newswire / March 10, 2025 / Nanomerics Ltd., a private speciality pharmaceutical company today announced that it had completed 28 consecutive days of administration in its OC134 Phase I trial - the SUNLIGHT trial and discharged the last volunteer from the trial. The last volunteer, last visit event concludes the clinical part of the trial. Nanomerics is pleased to report that the trial met its primary endpoints. All volunteers (n=10) completed the 28-day consecutive twice daily (12 hours apart) dosing schedule with either MET eye drops or OC134 eye drops, and all volunteers completed the 56 day follow up visits, with no dropouts.
There were no treatment-related adverse events of moderate or severe severity reported during the clinical and follow-up phases of the trial and there were no treatment-related clinically significant individual changes from baseline or notable trends in safety assessments including safety bloods, vital signs, eye examination, 12 lead ECGs and urinalysis.
The topical administration of MET and OC134 eye drops on 56 consecutive occasions was well tolerated by healthy volunteers under the conditions of trial and no treatment-related items of concern were reported during the follow up visits.
Approval was granted for the OC134 and MET tolerability study by the UK Medicinal and Healthcare Products Regulatory Agency (MHRA) and the study was conducted by Quotient Sciences at its Nottingham, UK Phase I study site according to Good Clinical Practice guidelines.
OC134 is an eye drop medicine candidate indicated for the topical treatment of moderate to severe allergic conjunctivitis, a condition for which a suitable non-steroidal topical ocular treatment, does not currently exist. OC134 is also indicated for the topical treatment of dry eye disease.
OC134 is powered by Nanomerics' Molecular Envelope Technology (MET), a non-irritant ocular penetration enhancer. Nanomerics' MET is a platform ocular penetration enhancer, that has been shown in preclinical studies to increase the penetration of active pharmaceutical ingredients (APIs) into the front of the eye; increasing ocular deposition up to 18-fold, when compared to conventional formulations. In preclinical studies, Nanomerics' MET also demonstrated the delivery of APIs to the retina from eye drops. Nanomerics has a pipeline of ocular assets that may now be tested in clinical studies and ultimately launched for the benefit of patients. Nanomerics' MET is now a clinical stage ocular excipient.
Professor Andreas G. Schätzlein, Nanomerics' Chief Executive Officer said,
'Our last volunteer, last visit event concludes the clinical and follow-up parts of the SUNLIGHT trial and we can now proudly state that Nanomerics is a clinical stage company, with assets applicable to a broad range of ophthalmology markets. Our goal has always been to discover and develop efficient, well-tolerated therapies for patients in areas of large unmet medical need and we embark on this new phase in our company, confident that we can deliver on this singularly important goal.'
Dr Nand Singh, Medical Director at Quotient Sciences commented,
We are pleased to state that the First-In-Human trial has been completed at our Nottingham, UK clinic for Nanomerics' OC134 Phase 1 SUNLIGHT trial. The trial met its primary endpoints, demonstrating favourable safety and tolerability profiles of MET and OC134 eye drops, administered as stated above, among healthy male and female volunteers. This excellent profile further warrants clinical trials in patient populations with moderate to severe allergic conjunctivitis, to further assess and achieve the critical proof of concept milestone for OC134.
About Nanomerics
Nanomerics Ltd is a speciality pharmaceutical company with state-of-the-art laboratories based in London, UK. Nanomerics was founded to commercialise its biocompatible polymer technologies for drug delivery and other applications. Nanomerics' proprietary technology is based on world leading know-how and scientific leadership in polymer nanotechnology. Nanomerics creates uniquely differentiated, patented pharmaceutical assets, underpinned by high quality science. For example, the company's Molecular Envelope Technology (MET) is a unique patented biocompatible polymer that delivers a step change in target tissue bioavailability. The founding scientists, Professor Dame Ijeoma F. Uchegbu and Professor Andreas G. Schätzlein developed the technology at the Universities of Strathclyde and Glasgow and, latterly at the UCL School of Pharmacy. Pharmaceutical product candidates in development include the eye drops: OC134 for the treatment of moderate to severe allergic conjunctivitis and dry eye disease, OC137 for the treatment of retinal diseases and OC135 for the treatment of glaucoma. For more information, please visit .
For press enquiries contact:
Pedro Margarido Head of Operations, Nanomerics Ltd.About Quotient Sciences
Quotient Sciences is a drug development and manufacturing accelerator providing integrated programmes and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, Quotient saves precious time and money in getting drugs to patients. Everything Quotient does for its customers is driven by an unswerving belief that ideas need to become solutions, and molecules need to become cures, fast, because humanity needs novel therapeutic solutions, fast. Quotient Sciences has been recognized as a multi-year winner of the CRO Leadership Awards in 2021, 2022, and 2024 and of the CDMO Leadership Awards in 2023. For more information, visit .
For press enquiries, contact:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
A British TV art expert who sold works to a suspected Hezbollah financier is sentenced to prison
LONDON (AP) — An art expert who appeared on the BBC's Bargain Hunt show was sentenced Friday to two and a half years in prison for failing to report his sale of pricey works to a suspected financier of Lebanon's militant Hezbollah group. At a previous hearing, Oghenochuko Ojiri, 53, had pleaded guilty to eight offenses under the Terrorism Act 2000. The art sales for about 140,000 pounds ($185,000) to Nazem Ahmad, a diamond and art dealer sanctioned by the U.K. and U.S. as a Hezbollah financier, took place between October 2020 and December 2021. The sanctions were designed to prevent anyone in the U.K. or U.S. from trading with Ahmad or his businesses. Ojiri, who also appeared on the BBC's Antiques Road Trip, faced a possible sentence of five years in prison in the hearing at London's Central Criminal Court, which is better known as the Old Bailey. In addition to the prison term, Justice Bobbie Cheema-Grubb said Ojiri faces an additional year on license — a period of time after a prison sentence ends when an offender must stay out of trouble or risk going back to prison. She told Ojiri he had been involved in a commercial relationship 'for prestige and profit' and that until his involvement with Ahmad, he was 'someone to be admired.' 'You knew about Ahmad's suspected involvement in financing terrorism and the way the art market can be exploited by someone like him," she said. "This is the nadir — there is one direction your life can go and I am confident that you will not be in front of the courts again.' The Met's investigation into Ojiri was carried out alongside Homeland Security in the U.S., which is conducting a wider investigation into alleged money laundering by Ahmad using shell companies. 'This prosecution, using specific Terrorism Act legislation, is the first of its kind and should act as a warning to all art dealers that we can, and will, pursue those who knowingly do business with people identified as funders of terrorist groups,' said Commander Dominic Murphy, head of the Metropolitan Police's Counter Terrorism Command. Ahmad was sanctioned in 2019 by the U.S. Treasury, which said he was a prominent Lebanon-based money launderer involved in smuggling blood diamonds, which are mined in conflict zones and sold to finance violence. Two years ago, the U.K. Treasury froze Ahmad's assets because he financed Hezbollah, the Iranian-backed Shiite militant organization that has been designated an international terrorist group. Following Ojiri's arrest in April 2023, the Met obtained a warrant to seize a number of artworks, including a Picasso and Andy Warhol paintings, belonging to Ahmad and held in two warehouses in the U.K. The collection, valued at almost 1 million pounds, is due to be sold with the funds to be reinvested back into the police, the Crown Prosecution Service and the Home Office.
The Hill
2 days ago
- The Hill
A British TV art expert who sold works to a suspected Hezbollah financier is sentenced to prison
LONDON (AP) — An art expert who appeared on the BBC's Bargain Hunt show was sentenced Friday to two and a half years in prison for failing to report his sale of pricey works to a suspected financier of Lebanon's militant Hezbollah group. Oghenochuko Ojiri, 53, pleaded guilty to eight offenses under the Terrorism Act 2000. The art sales took place between October 2020 and December 2021. Ojiri, who also appeared on the BBC's Antiques Road Trip, faced a possible sentence of five years in prison in the hearing at London's Central Criminal Court, which is better known as the Old Bailey. In addition to the prison term, Justice Bobbie Cheema-Grubb said Ojiri faces an additional year on license. Ojiri sold about 140,000 pounds ($185,000) worth of artworks to Nazem Ahmad, a diamond and art dealer sanctioned by the U.K. and U.S. as a Hezbollah financier. The sanctions were designed to prevent anyone in the U.K. or U.S. from trading with Ahmad or his businesses. 'This prosecution, using specific Terrorism Act legislation, is the first of its kind and should act as a warning to all art dealers that we can, and will, pursue those who knowingly do business with people identified as funders of terrorist groups,' said Commander Dominic Murphy, head of the Metropolitan Police's Counter Terrorism Command. The Met's investigation into Ojiri was carried out alongside Homeland Security in the U.S., which is conducting a wider investigation into alleged money laundering by Ahmad using shell companies. Ahmad was sanctioned in 2019 by the U.S. Treasury, which said he was a prominent Lebanon-based money launderer involved in smuggling blood diamonds, which are mined in conflict zones and sold to finance violence. Two years ago, the U.K. Treasury froze Ahmad's assets because he financed Hezbollah, the Iranian-backed Shiite militant organization that has been designated an international terrorist group. Following Ojiri's arrest in April 2023, the Met obtained a warrant to seize a number of artworks, including a Picasso and Andy Warhol paintings, belonging to Ahmad and held in two warehouses in the U.K. The collection, valued at almost 1 million pounds, is due to be sold with the funds to be reinvested back into the police, the Crown Prosecution Service and the Home Office.
San Francisco Chronicle
2 days ago
- San Francisco Chronicle
A British TV art expert who sold works to a suspected Hezbollah financier is sentenced to prison
LONDON (AP) — An art expert who appeared on the BBC's Bargain Hunt show was sentenced Friday to two and a half years in prison for failing to report his sale of pricey works to a suspected financier of Lebanon's militant Hezbollah group. Oghenochuko Ojiri, 53, pleaded guilty to eight offenses under the Terrorism Act 2000. The art sales took place between October 2020 and December 2021. Ojiri, who also appeared on the BBC's Antiques Road Trip, faced a possible sentence of five years in prison in the hearing at London's Central Criminal Court, which is better known as the Old Bailey. In addition to the prison term, Justice Bobbie Cheema-Grubb said Ojiri faces an additional year on license. Ojiri sold about 140,000 pounds ($185,000) worth of artworks to Nazem Ahmad, a diamond and art dealer sanctioned by the U.K. and U.S. as a Hezbollah financier. The sanctions were designed to prevent anyone in the U.K. or U.S. from trading with Ahmad or his businesses. 'This prosecution, using specific Terrorism Act legislation, is the first of its kind and should act as a warning to all art dealers that we can, and will, pursue those who knowingly do business with people identified as funders of terrorist groups,' said Commander Dominic Murphy, head of the Metropolitan Police's Counter Terrorism Command. The Met's investigation into Ojiri was carried out alongside Homeland Security in the U.S., which is conducting a wider investigation into alleged money laundering by Ahmad using shell companies. Ahmad was sanctioned in 2019 by the U.S. Treasury, which said he was a prominent Lebanon-based money launderer involved in smuggling blood diamonds, which are mined in conflict zones and sold to finance violence. Two years ago, the U.K. Treasury froze Ahmad's assets because he financed Hezbollah, the Iranian-backed Shiite militant organization that has been designated an international terrorist group. Following Ojiri's arrest in April 2023, the Met obtained a warrant to seize a number of artworks, including a Picasso and Andy Warhol paintings, belonging to Ahmad and held in two warehouses in the U.K. The collection, valued at almost 1 million pounds, is due to be sold with the funds to be reinvested back into the police, the Crown Prosecution Service and the Home Office.
